{"drugs":["ACAM2000","Dryvax","Smallpox Vaccine"],"mono":{"0":{"id":"927732-s-0","title":"Generic Names","mono":"Smallpox Vaccine"},"1":{"id":"927732-s-1","title":"Dosing and Indications","sub":{"0":{"id":"927732-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Monkeypox; Prophylaxis:<\/b> follow same procedures as used for primary smallpox vaccination<\/li><li><b>Smallpox, High-risk individuals; Prophylaxis:<\/b> (primary vaccination) with bifurcated needle, pick up and deposit one droplet (0.0025 mL) of vaccine on the skin; percutaneously vaccinate through the drop with 15 jabs within a diameter about 5 mm, using the multiple puncture technique<\/li><li><b>Smallpox, High-risk individuals; Prophylaxis:<\/b> (revaccination every 3 years in persons at continued high risk of exposure) with bifurcated needle, pick up and deposit one droplet (0.0025 mL) of vaccine on the skin; percutaneously vaccinate through the drop with 15 punctures, using the multiple puncture technique<\/li><\/ul>"},"1":{"id":"927732-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy of live smallpox (vaccinia) vaccine is not established in the age groups from birth to age 16 years<\/li><li><b>Monkeypox; Prophylaxis:<\/b> follow same procedures as used for primary smallpox vaccination<\/li><li><b>Smallpox, High-risk individuals; Prophylaxis:<\/b> (adolescents 16 years and older), primary vaccination with bifurcated needle, pick up and deposit one droplet (0.0025 mL) of vaccine on the skin; percutaneously vaccinate through the drop with 15 jabs within a diameter about 5 mm, using the multiple puncture technique<\/li><li><b>Smallpox, High-risk individuals; Prophylaxis:<\/b> (adolescents 16 years and older), revaccination every 3 years in persons at continued high risk of exposure with bifurcated needle, pick up and deposit one droplet (0.0025 mL) of vaccine on the skin; percutaneously vaccinate through the drop with 15 punctures, using the multiple puncture technique<\/li><\/ul>"},"3":{"id":"927732-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Smallpox, High-risk individuals; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Monkeypox; Prophylaxis<\/li><li>Smallpox, Post-exposure; Prophylaxis<\/li><li>Smallpox, Pre-exposure; Prophylaxis<\/li><\/ul>"}}},"2":{"id":"927732-s-2","title":"Black Box Warning","mono":"<b>Injection (Powder for Solution)<\/b><br\/>Myocarditis, pericarditis, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum resulting in permanent sequelae or death, ocular complications and blindness and fetal death, have occurred following primary vaccination or revaccination. Certain individuals are at an increased risk which may lead to severe disability, permanent neurological sequelae and\/or death.<br\/>"},"3":{"id":"927732-s-3","title":"Contraindications\/Warnings","sub":[{"id":"927732-s-3-9","title":"Contraindications","mono":"severe immunodeficiency, including individuals undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation; risk of severe localized or systemic infection with vaccinia <br\/>"},{"id":"927732-s-3-10","title":"Precautions","mono":"<ul><li>cardiac disease or a history of cardiac disease; increased risk of serious complications, severe disability, permanent neurological sequelae or death<\/li><li>close contacts with vaccinee with active vaccination lesions, avoid; live vaccinia can shed and be transmitted, leading to inadvertent auto-inoculation and exposure of the vaccine, further increased in risk among immunocompromised individuals and patients<\/li><li>eczema, history of eczema, or other acute or chronic exfoliative skin conditions, regardless of severity; increased risk of eczema vaccinatum, and potential of developing serious complications, severe disability, permanent neurological sequelae or death<\/li><li>eye disease treated with topical steroids; increased risk of ocular vaccinia and potential for developing keratitis, corneal scarring and blindness<\/li><li>HIV\/AIDS, cellular or humoral immune deficiency (congenital or acquired); increased risk of developing severe localized or systemic infection with vaccinia<\/li><li>immunosuppressive therapy, including radiation therapy, treatment with antimetabolites, alkylating agents, or high-dose corticosteroids (greater than 10 mg prednisone\/day or equivalent for 2 weeks or longer); increased risk of developing severe localized or systemic infection with vaccinia<\/li><li>infants less than 12 months of age; increased risk of serious complications, severe disability, permanent neurological sequelae or death<\/li><li>myocarditis and pericarditis; increased risk even among healthy individuals<\/li><li>pregnancy or whose household contacts are pregnant, avoid contacts and medically-unnecessary exposure; risk of fetal vaccinia and rare fetal death<\/li><li>allergies to polymyxin B sulfate or neomycin sulfate, components of smallpox vaccine; increased risk of developing adverse events<\/li><li>cardiac risk factors for ischemic coronary disease, hypertension, diabetes, hypercholesterolemia, heart disease at age 50 in first-degree relative, smoking; increased risk of potentially fatal ischemic cardiac events, serious complications, severe disability, permanent neurological sequelae<\/li><li>donation of blood or organs; transmission of virus possible during first 30 days following vaccination<\/li><li>generalized malignancy; increased risk of developing severe localized or systemic infection with vaccinia<\/li><li>leukemia, lymphomas of any type, and other malignant neoplasms affecting the bone-marrow or lymphatic systems, history of; increased risk of developing progressive vaccinia<\/li><li>organ transplantation patients; increased risk of developing severe localized or systemic infection with vaccinia<\/li><li>serious neurologic adverse effects including encephalitis, encephalomyelitis, and encephalopathy; may occur following primary vaccination or revaccination<\/li><li>serious skin reactions, including progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major, eczema vaccinatum; may occur following primary vaccination or revaccination<\/li><li>transmission of live vaccinia virus; autoinoculation and contact transmission possible until scab separates from the vaccination site<\/li><li>management of complications; for additional information and guidance, physicians can call the CDC (404) 639-3670 or (404) 639-2888<\/li><li>adverse event reporting; Acambis Inc. (866) 440-9440 or VAERS (800) 822-7967, or https:\/\/vaers.hhs.gov<\/li><\/ul>"},{"id":"927732-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"927732-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"927732-s-4","title":"Drug Interactions","sub":{"1":{"id":"927732-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Alemtuzumab (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Teriflunomide (theoretical)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"927732-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Cytomegalovirus Immune Globulin, Human (probable)<\/li><li>Hepatitis B Immune Globulin (probable)<\/li><li>Leflunomide (established)<\/li><li>Rabies Immune Globulin (probable)<\/li><li>Respiratory Syncytial Virus Immune Globulin, Human (probable)<\/li><li>Tetanus Immune Globulin (probable)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><li>Varicella-Zoster Immune Globulin (probable)<\/li><\/ul>"}}},"5":{"id":"927732-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (22% to 24%), Injection site pruritus (82% to 92%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (12% to 16%), Nausea (10% to 19%)<\/li><li><b>Immunologic:<\/b>Pain of lymph node (19% to 57%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (27% to 46%)<\/li><li><b>Neurologic:<\/b>Headache (35% to 51%)<\/li><li><b>Other:<\/b>Fatigue (34% to 48%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial ischemia, Myocarditis, Pericarditis<\/li><li><b>Dermatologic:<\/b>Complication of smallpox vaccination, Eczema vaccinatum, Erythema multiforme, Generalized vaccinia, Injection site reaction<\/li><li><b>Immunologic:<\/b>Vaccinia, Fetal (rare)<\/li><li><b>Neurologic:<\/b>Encephalopathy, Post-immunization encephalitis, Postvaccinal encephalomyelitis<\/li><li><b>Ophthalmic:<\/b>Disorder of eye, Accidental autoinoculation including conjunctivitis, blepharitis, keratitis, blindness<\/li><li><b>Other:<\/b>Complication due to vaccination, Death (rare)<\/li><\/ul>"},"6":{"id":"927732-s-6","title":"Drug Name Info","sub":{"0":{"id":"927732-s-6-17","title":"US Trade Names","mono":"<ul><li>Dryvax<\/li><li>ACAM2000<\/li><\/ul>"},"2":{"id":"927732-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"927732-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"927732-s-7","title":"Mechanism Of Action","mono":"Smallpox vaccine is prepared from live vaccinia virus which provides active immunization against smallpox disease. It results in viral multiplication, immunity and cellular hypersensitivity.<br\/>"},"9":{"id":"927732-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>(injection): for percutaneous use only; use multiple-puncture technique<\/li><li>remove vial from cold storage and brought to room temperature; dilute the lyophilized vaccine with 0.3 mL of diluent provided using aseptic techniques<\/li><li>preferred vaccination site for is the skin over the insertion of the deltoid muscle or the posterior aspect of the arm over the triceps muscle<\/li><li>vaccine remaining on the skin after vaccination should be blotted off the site<\/li><li>thorough hand washing after changing the bandage or after any contact with the vaccination site is stressed<\/li><li>care should be taken to avoid contamination of multidose vials; the same needle should never be dipped into the vaccine vial more than once<\/li><li>cover vaccination site with a porous bandage until the scab has separated and the skin has healed; contaminated gauze should be sealed in a plastic bag before disposal.<\/li><li>recently vaccinated healthcare workers should avoid contact with patients or ensure the vaccination site is well-covered; good hand-washing technique is stressed<\/li><li>vaccine vials, stoppers, needles, and any gauze or cotton contacting the vaccine should be discarded in leak-proof, puncture-proof biohazard containers, and be disposed of appropriately<\/li><\/ul>"},"10":{"id":"927732-s-10","title":"Monitoring","mono":"<ul><li>vesicular or pustular lesion at vaccination site 6 to 8 days after vaccination; indicative of the acquisition of protective immunity<\/li><li>symptoms of myocarditis or pericarditis such as chest pain, raised troponin\/cardiac enzymes, or ECG abnormalities should be monitored.<\/li><li>signs and symptoms of serious complications such as generalized vaccinia, eczema vaccinatum, progressive vaccinia, or post-vaccinial encephalitis.<\/li><\/ul>"},"13":{"id":"927732-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid contact with pregnant females until injection site has completely healed.<\/li><li>Inadvertent autoinoculation to other body sites or other people may occur. Counsel patient that all contact with vaccination site should be avoided.<\/li><li>Accidental autoinoculation may cause ophthalmic effects including conjunctivitis, blepharitis, keratitis, or blindness.<\/li><li>Patient should report signs\/symptoms of encephalitis, eczema, or cardiac dysfunction.<\/li><li>Advise patient to keep injection site well-covered with a porous bandage until the scab has separated and skin has healed.<\/li><li>Instruct patient to change bandage every 1 to 2 days. Patient should seal contaminated gauze\/bandages in a plastic bag before disposal and wash hands thoroughly after applying a new bandage.<\/li><\/ul>"}}}